1-ethyl-2-pyrrolidinylmethyl-alpha-phenylcyclopentylglycolate, 1-ethyl-3-piperidyl-alpha-phenylcyclopentylglycolate drug combination has been researched along with phencyclidine in 2 studies
| Studies (1-ethyl-2-pyrrolidinylmethyl-alpha-phenylcyclopentylglycolate, 1-ethyl-3-piperidyl-alpha-phenylcyclopentylglycolate drug combination) | Trials (1-ethyl-2-pyrrolidinylmethyl-alpha-phenylcyclopentylglycolate, 1-ethyl-3-piperidyl-alpha-phenylcyclopentylglycolate drug combination) | Recent Studies (post-2010) (1-ethyl-2-pyrrolidinylmethyl-alpha-phenylcyclopentylglycolate, 1-ethyl-3-piperidyl-alpha-phenylcyclopentylglycolate drug combination) | Studies (phencyclidine) | Trials (phencyclidine) | Recent Studies (post-2010) (phencyclidine) |
|---|---|---|---|---|---|
| 20 | 0 | 0 | 28,294 | 387 | 7,796 |
| Protein | Taxonomy | 1-ethyl-2-pyrrolidinylmethyl-alpha-phenylcyclopentylglycolate, 1-ethyl-3-piperidyl-alpha-phenylcyclopentylglycolate drug combination (IC50) | phencyclidine (IC50) |
|---|---|---|---|
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | 0.1299 | |
| Lysosomal Pro-X carboxypeptidase | Homo sapiens (human) | 0.091 | |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | 0.1299 | |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 0.1299 | |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | 0.1299 | |
| Glutamate receptor ionotropic, NMDA 1 | Homo sapiens (human) | 0.5563 | |
| Glutamate receptor ionotropic, NMDA 2A | Homo sapiens (human) | 0.205 | |
| Glutamate receptor ionotropic, NMDA 2B | Homo sapiens (human) | 1.2589 | |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | 0.1299 | |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | 0.1299 | |
| Sigma non-opioid intracellular receptor 1 | Rattus norvegicus (Norway rat) | 0.53 | |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | 0.1299 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alkadhi, KA; Branisteanu, DD; Epstein, PM; Henderson, EG; Lambert, JJ; Reynolds, LS; Smilowitz, H; Volle, RL | 1 |
| RAJOTTE, P | 1 |
1 review(s) available for 1-ethyl-2-pyrrolidinylmethyl-alpha-phenylcyclopentylglycolate, 1-ethyl-3-piperidyl-alpha-phenylcyclopentylglycolate drug combination and phencyclidine
| Article | Year |
|---|---|
[PSYCHODYSLEPTIC DRUGS. II. SOME PROBLEMS RELATED TO THEIR USE].
Topics: Cerebral Cortex; Chemical Phenomena; Chemistry; Classification; Dosage Forms; Drug Combinations; Electroencephalography; Glycolates; Hallucinogens; Humans; Indoles; Lysergic Acid Diethylamide; Mescaline; Phencyclidine; Piperidines; Psychopharmacology; Pyrrolidines; Schizophrenia; Toxicology | 1964 |
1 other study(ies) available for 1-ethyl-2-pyrrolidinylmethyl-alpha-phenylcyclopentylglycolate, 1-ethyl-3-piperidyl-alpha-phenylcyclopentylglycolate drug combination and phencyclidine
| Article | Year |
|---|---|
Ketamine and ditran block end-plate ion conductance and [3H]phencyclidine binding to electric organ membrane.
Topics: Animals; Drug Combinations; Electric Organ; Glycolates; Hydrogen-Ion Concentration; In Vitro Techniques; Ion Channels; Ketamine; Neurotransmitter Agents; Phencyclidine; Piperidines; Pyrrolidines; Rana pipiens; Receptors, Cholinergic; Torpedo | 1982 |